213 related articles for article (PubMed ID: 35413618)
1. Topoisomerase I inhibitors: Challenges, progress and the road ahead.
Talukdar A; Kundu B; Sarkar D; Goon S; Mondal MA
Eur J Med Chem; 2022 Jun; 236():114304. PubMed ID: 35413618
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries.
Cinelli MA
Med Res Rev; 2019 Jul; 39(4):1294-1337. PubMed ID: 30456874
[TBL] [Abstract][Full Text] [Related]
3. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
5. The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Martín-Encinas E; Selas A; Palacios F; Alonso C
Expert Opin Drug Discov; 2022 Jun; 17(6):581-601. PubMed ID: 35321631
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor.
Yu Q; Chen Y; Yang H; Zhang HL; Agama K; Pommier Y; An LK
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):818-822. PubMed ID: 30907213
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
8. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
9. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.
Seol Y; Zhang H; Agama K; Lorence N; Pommier Y; Neuman KC
Mol Cancer Ther; 2015 Nov; 14(11):2552-9. PubMed ID: 26351326
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
11. Diversity of DNA topoisomerases I and inhibitors.
Pommier Y
Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
[TBL] [Abstract][Full Text] [Related]
12. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.
Zhang XR; Wang HW; Tang WL; Zhang Y; Yang H; Hu DX; Ravji A; Marchand C; Kiselev E; Ofori-Atta K; Agama K; Pommier Y; An LK
J Med Chem; 2018 Nov; 61(22):9908-9930. PubMed ID: 30336023
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Majumdar P; Bathula C; Basu SM; Das SK; Agarwal R; Hati S; Singh A; Sen S; Das BB
Eur J Med Chem; 2015 Sep; 102():540-51. PubMed ID: 26312433
[TBL] [Abstract][Full Text] [Related]
14. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors.
Sheng C; Miao Z; Zhang W
Curr Med Chem; 2011; 18(28):4389-409. PubMed ID: 21861816
[TBL] [Abstract][Full Text] [Related]
15. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.
Nguyen TX; Abdelmalak M; Marchand C; Agama K; Pommier Y; Cushman M
J Med Chem; 2015 Apr; 58(7):3188-208. PubMed ID: 25811317
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors.
Yu Q; Yang H; Zhu TW; Yu LM; Chen JW; Gu LQ; Huang ZS; An LK
Eur J Med Chem; 2018 May; 152():195-207. PubMed ID: 29705710
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
20. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
